Suppr超能文献

2013 年至 2019 年期间华东地区身材矮小患者的回顾性分析。

A Retrospective Analysis of Patients with Short Stature in Eastern China between 2013 and 2019.

机构信息

Department of Endocrinology, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, Shandong 272029, China.

Department of Endocrinology, Qingdao University, Qingdao 266000, China.

出版信息

Biomed Res Int. 2021 Apr 20;2021:6640026. doi: 10.1155/2021/6640026. eCollection 2021.

Abstract

OBJECTIVE

To identify the aetiology of growth and development diseases and assess the long-term effectiveness of recombinant human growth hormone (rhGH) therapy in a real-life clinical setting and provide better guidance in clinical strategy and decision making.

METHODS

This retrospective study included 1145 children and adolescents with short stature admitted to the Department of Endocrinology, Affiliated Hospital of Jining Medical University, from January 2013 to December 2019, of whom 484 received rhGH treatment. The related anthropometrics and laboratory examinations were assessed in all participants.

RESULTS

A total of 1145 children and adolescents with short stature aged 10.5 ± 3.3 years, including 740 boys and 405 girls, were analysed in this study. The number of children and adolescents with short stature gradually increased per year from 2013 to 2019. The mean pretreatment height standard deviation score (SDS) and insulin-like growth factor-1 SDS were -2.93 ± 1.05 and -1.01 (-1.83--0.16), respectively. The majority of the children (658, 57.47%) were prepubescent. In total, 484 subjects aged 10.6 ± 3.2 years received rhGH and were followed up, and among them, 292 children were treated for more than one year. As the treatment time increased, the children's height SDS gradually increased, and most of them attained a height SDS within the normal range. The mean height SDS in children who were treated for more than one year was -3.0 ± 1.0 at baseline and gradually increased to -0.8 ± 0.3 by year 6. The results were consistent across subgroups of different aetiologies of short stature.

CONCLUSIONS

Increasing attention has been given to the height of children during the period of 2013-2019 in eastern China. The present findings indicate that children with short stature need to be referred to a specialist centre to diagnose the cause of growth failure and that short children receiving rhGH therapy show a significant increase in height over time.

摘要

目的

在真实临床环境中确定生长发育疾病的病因,并评估重组人生长激素(rhGH)治疗的长期疗效,为临床策略和决策提供更好的指导。

方法

本回顾性研究纳入了 2013 年 1 月至 2019 年 12 月期间在济宁医学院附属医院内分泌科就诊的 1145 例身材矮小的儿童和青少年患者,其中 484 例接受 rhGH 治疗。所有参与者均评估了相关的人体测量学和实验室检查结果。

结果

本研究共分析了 1145 例年龄为 10.5 ± 3.3 岁的身材矮小的儿童和青少年患者,其中男 740 例,女 405 例。2013 年至 2019 年,身材矮小的儿童和青少年人数逐年增加。治疗前身高标准差评分(SDS)和胰岛素样生长因子-1 SDS 均值分别为-2.93 ± 1.05 和-1.01(-1.83~-0.16)。大多数儿童(658 例,57.47%)处于青春前期。共 484 例年龄为 10.6 ± 3.2 岁的患者接受 rhGH 治疗并进行了随访,其中 292 例治疗时间超过 1 年。随着治疗时间的延长,儿童的身高 SDS 逐渐增加,大多数儿童的身高 SDS 达到正常范围。治疗时间超过 1 年的儿童在基线时的平均身高 SDS 为-3.0 ± 1.0,到第 6 年逐渐增加到-0.8 ± 0.3。不同矮小病因亚组的结果一致。

结论

2013-2019 年期间,中国东部地区对儿童身高的关注度不断提高。本研究结果表明,身材矮小的儿童需要转至专科中心以明确生长障碍的病因,且接受 rhGH 治疗的矮小儿童身高随时间推移显著增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/8081605/f9ac7bbfa5d5/BMRI2021-6640026.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验